This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: I08 (Multiple valve diseases) | Special Copayment Reduction: V192 (Special Copayment Reduction for heart disease: copayment 5% for up to 30 days from the registration date) |
| B. Synonyms | Combined valvular disease, rheumatic multivalvular disease, mixed multivalvular stenosis and regurgitation. I08.0: mitral and aortic valve involvement, I08.1: mitral and tricuspid valve involvement, I08.2: aortic and tricuspid valve involvement, I08.3: involvement of all three valves. |
| C. Adult onset | Rheumatic multivalvular disease progresses over decades after childhood rheumatic fever and presents in the 30s~60s with combined heart failure symptoms. The lesions of each valve interact to cause complex hemodynamic disturbances. |
| 1. History | Multivalvular disease long recognized as the natural course of rheumatic heart disease. Advances in combined valve surgery techniques from the 1970s~80s. The 2020s: the era of the Heart Team approach and combined interventions. |
| 2. Causes | Rheumatic fever is the most common cause (especially in developing countries). Non-rheumatic causes such as degenerative, infectious (endocarditis), congenital, and radiation-induced can also involve multiple valves. |
| 3. Genetics | In cases of rheumatic origin, HLA-related immunogenetic susceptibility. Multivalvular lesions may occur in hereditary connective tissue disorders (Marfan, Ehlers-Danlos). Polygenic complex inheritance. |
| 4. General epidemiology | About 10~20% of valve surgery patients have multivalvular disease. Rheumatic multivalvular disease predominates in low- and middle-income countries. In developed countries, multivalvular disease of degenerative and mixed causes is increasing. |
| 5. Pathophysiology | Hemodynamic interactions between the lesions of each valve are complex. Upstream valve stenosis masks downstream valve lesions. The cascade of left heart disease → pulmonary hypertension → right heart failure → functional tricuspid regurgitation. |
| 6. Symptoms | Combined: dyspnea, fatigue, palpitations, lower limb edema, ascites, chest pain, syncope. Symptoms of each valve lesion may overlap or offset one another, making it difficult to gauge severity. |
| 7. Signs | Multiple heart murmurs, altered heart sounds, findings of pulmonary hypertension. Murmurs from each valve interfere with one another, complicating interpretation of auscultation. Severity cannot be assessed without echocardiography. |
| 8. Screening | Comprehensive echocardiography including evaluation of all valves in patients with rheumatic heart disease. Use of cardiac MRI and CT before cardiac planning. Exercise stress testing to assess functional reserve. |
| 9. Diagnosis | Comprehensive echocardiography (area, pressure gradient, and regurgitation severity of each valve, left and right ventricular function, pulmonary artery pressure). Cardiac CT (anatomy, calcification). MRI (ventricular volume and function). Cardiac catheterization to measure pressures and cardiac output. |
| 10. Treatment | With two or more severe lesions, combined valve surgery is recommended after Heart Team discussion (Class I). With a combination of severe and non-severe lesions, treat based on the more severe lesion. Consider a hybrid approach. |
| 11. Prognosis | Prognosis poorer than single-valve disease. 30-day mortality after combined valve surgery about 5~10%. 10-year survival rate 50~70%. Left ventricular function and the degree of pulmonary hypertension are the key prognostic factors. |
| 12. Prevention | In cases of rheumatic origin, secondary prophylaxis (benzathine penicillin G) is key to preventing further valve damage. Anticoagulation for atrial fibrillation and prevention of embolism. Optimization of heart failure management. |
| 13. References | Treatment of multiple valve disease: surgery, structural intervention, or both? (European Heart Journal Supplements, 2023) … and 9 other papers |
Multivalvular disease (MVD) has long been recognized as the natural course of rheumatic heart disease. In 19th-century pathologic studies, fibrosis and adhesions spanning several valves were observed at autopsy of patients with rheumatic fever, confirming that recurrent endocarditis simultaneously involves several valves. However, in an era with no possibility of treatment, there was little practical benefit in making the clinical distinction.
With the introduction of cardiopulmonary bypass and advances in open-heart surgery, combined valve surgery was first attempted in the 1960s~70s. Initially, the high surgical risk and long cardiopulmonary bypass time associated with operating on several valves at once were problems. In the 1970s~80s, as bioprosthetic and mechanical valves improved and surgical techniques advanced, the outcomes of combined valve surgery improved, and with the development of heart valve repair techniques by Carpentier and others, attempts were also made to correct combined lesions without valve replacement.
In the 21st century, advances in transcatheter valve interventions such as TAVI and MitraClip (transcatheter mitral valve repair) have made hybrid or staged intervention strategies possible in high-risk patients with multivalvular disease. Currently, a multidisciplinary 'Heart Team' approach composed of cardiac surgeons, cardiologists, anesthesiologists, radiologists, and others has become the standard for treating multivalvular disease.
The most common cause of multivalvular disease in low- and middle-income countries is still rheumatic fever. Rheumatic endocarditis most often involves the mitral valve but can also involve the aortic and tricuspid valves and, rarely, the pulmonary valve. Multivalvular disease develops as fibrotic changes accumulate in several valves with repeated episodes.
In developed countries, multivalvular disease due to non-rheumatic causes is increasing. Degenerative calcification can involve both the aortic valve and the mitral annulus and is an important cause in the elderly population. Infective endocarditis destroys several valves simultaneously or sequentially, causing multivalvular disease. Connective tissue diseases (Marfan syndrome, Ehlers-Danlos syndrome) cause prolapse and regurgitation of several valves. Radiation therapy causes fibrosis and stenosis of several valves decades later. Lupus (Libman-Sacks endocarditis), antiphospholipid antibody syndrome, and carcinoid tumors also cause multivalvular involvement.
The genetic basis of multivalvular disease varies by cause. In multivalvular disease of rheumatic origin, the same immunogenetic susceptibility of rheumatic fever applies, including associations with HLA class II genes. Multivalvular involvement due to hereditary connective tissue disorders includes Marfan syndrome (FBN1 gene variants, autosomal dominant), Ehlers-Danlos syndrome (collagen gene variants), Loeys-Dietz syndrome (TGFBR1/2 gene variants), and others.
In patients with a bicuspid aortic valve (BAV), accompanying mitral valve prolapse is observed at a higher rate than in normal individuals, suggesting common involvement of certain connective tissue development genes. NOTCH1 gene variants are associated with bicuspid aortic valve and related aortic abnormalities. In general, the genetics of multivalvular disease are complex and, except for single-cause cases, follow polygenic inheritance.
The exact prevalence of multivalvular disease varies with the defining criteria, but about 10~20% of patients undergoing valve surgery are estimated to have multivalvular disease. In low- and middle-income countries (sub-Saharan Africa, South Asia, etc.), rheumatic multivalvular disease is the main cause of valve surgery, and many patients present with involvement of three or more valves.
In developed countries, multivalvular disease of degenerative cause is increasing with population aging. In particular, the combination of aortic stenosis and functional tricuspid regurgitation, or of mitral regurgitation and aortic stenosis, is commonly observed. According to a European multidisciplinary valve study (EACVI), the proportion of patients with two or more moderate or greater valve lesions seen in clinical practice is increasing, and referrals to specialized centers are increasing because of the complexity of treatment decisions.
The hemodynamic complexity of multivalvular disease stems from the interactions by which each valve lesion affects the others. The most important concept is masking of downstream lesions by upstream lesions. For example, with severe mitral stenosis, preload to the left ventricle is reduced, so the murmur and pressure gradient of coexisting aortic stenosis may be measured lower than they actually are. In this case, after the mitral stenosis is corrected, the so-called 'unmasking' phenomenon occurs, in which the severity of the aortic stenosis becomes clearly apparent.
When left-sided valve disease causes pulmonary hypertension, the right ventricle dilates and the tricuspid annulus stretches, producing functional tricuspid regurgitation. This functional tricuspid regurgitation worsens systemic venous congestion, adding symptoms of right heart failure, and reduces renal perfusion, causing diuretic resistance and declining renal function. In combined valve lesions, each lesion simultaneously affects ventricular preload and afterload, so it is difficult to accurately determine the overall hemodynamic status from echocardiographic indices of individual valve lesions alone.
The symptoms of multivalvular disease appear as overlapping or offsetting symptoms from each lesion. Symptoms of pulmonary venous hypertension due to left-sided valve lesions (exertional dyspnea, orthopnea, paroxysmal nocturnal dyspnea) and symptoms of systemic venous congestion due to right heart failure (lower limb edema, ascites, hepatic congestion, fatigue) may occur simultaneously. In combined lesions, a paradoxical phenomenon may also occur in which upstream stenosis restricts downstream blood flow and pulmonary edema symptoms are actually lessened.
Palpitations and atrial fibrillation commonly accompany it, and the sudden onset of atrial fibrillation causes abrupt worsening of symptoms. When aortic stenosis is severe, angina and exertional syncope may occur. Fatigue and reduced exercise tolerance may be prominent from early on because cardiac output decreases stepwise in combined valve lesions. Thromboembolic stroke may also occur in association with thrombus formation in the left atrium.
On physical examination in multivalvular disease, multiple heart murmurs are heard, and they may overlap so that it is difficult to distinguish the murmurs of individual valve lesions. For example, the diastolic murmur of mitral stenosis and the holosystolic murmur of tricuspid regurgitation may be heard at the same time, and the high-pitched diastolic murmur of aortic regurgitation may be confused with the diastolic murmur of mitral stenosis. For these reasons, it is practically impossible to assess the exact severity of multivalvular disease from auscultation findings alone, and echocardiography is essential.
Attempting to evaluate multivalvular disease by auscultation alone without echocardiography can be a cause of clinical error. When pulmonary hypertension has progressed, an accentuated P2, a Graham Steell murmur (pulmonary regurgitation), and a subxiphoid impulse due to right ventricular hypertrophy appear. Signs of right heart failure include jugular venous distension, hepatomegaly, ascites, and lower limb edema. With accompanying atrial fibrillation, an irregular pulse is palpated.
The screening strategy for comprehensive evaluation of multivalvular disease is systematic evaluation of all valves during routine echocardiography in patients with rheumatic heart disease. Even in patients diagnosed with a single-valve lesion, involvement of adjacent valves should be checked regularly. In particular, aortic and tricuspid involvement is common in patients with rheumatic mitral stenosis, so evaluation of all valves must be included when mitral stenosis is diagnosed.
Exercise stress echocardiography is useful for assessing the functional severity of combined lesions not captured by resting echocardiography. It is performed when symptoms and resting echocardiographic findings do not match, or when preoperative assessment of cardiopulmonary reserve is needed. Cardiac MRI can accurately quantify ventricular volume, function, and valvular regurgitant volume, complementing the limitations of echocardiography. Cardiac CT is essential for evaluating the degree of calcification and anatomic details.
Diagnosis and severity assessment of multivalvular disease center on comprehensive echocardiography. The morphology, mobility, area, pressure gradient, and regurgitation severity of each valve (mitral, aortic, tricuspid, pulmonary) should be evaluated systematically. At the same time, left ventricular systolic and diastolic function, right ventricular function, left and right atrial size, and pulmonary artery systolic pressure (RVSP) are measured together.
Considering the mutual masking effects of combined lesions, the severity of each valve lesion should be evaluated independently, while the hemodynamic interactions are reflected in the interpretation. When severity indices conflict or fall at borderline values, cardiac MRI (direct measurement of regurgitant volume, quantification of left ventricular function) is useful. Cardiac catheterization is performed when valve severity and cardiac output cannot be accurately assessed by echocardiography or when preoperative coronary evaluation is needed. When planning surgery, cardiac CT is used to evaluate valve morphology, calcification, and aortic anatomy.
Treatment decisions in multivalvular disease are made through Heart Team discussion, integrating the severity of each valve lesion, symptoms, ventricular function, the patient's surgical risk, and technical feasibility. Current guidelines (ESC 2021, ACC/AHA 2020) recommend treating two or more severe valve lesions simultaneously (Class I), and with a combination of severe and non-severe lesions, the principle is to base the treatment decision on the more severe lesion.
Surgical combined valve surgery repairs or replaces several valves simultaneously and is a specialized technique of modern cardiac surgery. Surgical risk (EuroSCORE II, STS score) is carefully calculated to decide between surgery and a hybrid/transcatheter approach. In high-risk surgical patients, a strategy of treating the most important valve first by a transcatheter approach and treating the rest in stages may be chosen. Medical therapy aims at symptom relief for each valve lesion (diuretics, anticoagulants, antihypertensives, etc.) and prevention of complications.
Multivalvular disease generally has a poorer prognosis than single-valve disease. If left without surgery, the 5-year survival rate in severe combined valve disease drops sharply to less than 50%. The 30-day in-hospital mortality of combined valve surgery is higher than that of single-valve surgery and is reported as about 5~15% for triple-valve surgery. The 10-year survival rate varies at about 50~70% depending on the valve combination and ventricular function.
Left ventricular ejection fraction (LVEF), the degree of pulmonary hypertension, preoperative right ventricular function, and renal function are the key factors determining long-term prognosis. The earlier surgery is performed, and the more ventricular function is preserved at the time of surgery, the better the prognosis. In rheumatic multivalvular disease, continuing secondary prophylaxis (benzathine penicillin G) is important even after surgery to prevent valve damage from new rheumatic episodes.
In multivalvular disease of rheumatic origin, secondary prophylaxis (regular benzathine penicillin G) is the most effective way to prevent progression of valve damage and new valve involvement from further rheumatic episodes. In patients with accompanying atrial fibrillation, warfarin-based anticoagulation prevents thromboembolic stroke. Optimal medical therapy for heart failure (ACE inhibitors, beta-blockers, diuretics) helps preserve ventricular function and improve symptoms. Preoperative cardiac rehabilitation programs may contribute to better surgical outcomes. In non-rheumatic causes (connective tissue disease, radiation exposure, etc.), early diagnosis and treatment of the underlying disease help prevent or delay valve involvement.
Lancellotti P, Tribouilloy C, Hagendorff A, et al. Treatment of multiple valve disease: surgery, structural intervention, or both? European Heart Journal Supplements. 2023;25(Suppl B):B21-B30. DOI: 10.1093/eurheartjsupp/suad028. PMID: 37091653.
Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. European Heart Journal. 2022;43(7):561-632. DOI: 10.1093/eurheartj/ehab395. PMID: 34453165.
Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease. Journal of the American College of Cardiology. 2021;77(4):e25-e197. DOI: 10.1016/j.jacc.2020.11.018. PMID: 33342586.
Iung B, Baron G, Butchart EG, et al. A prospective survey of patients with valvular heart disease in Europe: the Euro Heart Survey on Valvular Heart Disease. European Heart Journal. 2003;24(13):1231-1243. DOI: 10.1016/S0195-668X(03)00201-X. PMID: 12831818.
Nkomo VT, Gardin JM, Skelton TN, et al. Burden of valvular heart diseases: a population-based study. Lancet. 2006;368(9540):1005-1011. DOI: 10.1016/S0140-6736(06)69208-8. PMID: 16980116.
Unger P, Clavel MA, Lindman BR, et al. Pathophysiology and management of multivalvular disease. Nature Reviews Cardiology. 2016;13(7):429-440. DOI: 10.1038/nrcardio.2016.57. PMID: 27063963.
Lancellotti P, Tribouilloy C, Hagendorff A, et al. European Association of Echocardiography recommendations for the assessment of valvular regurgitation. Part 1: aortic and pulmonary regurgitation. European Journal of Echocardiography. 2010;11(3):223-244. DOI: 10.1093/ejechocard/jeq030. PMID: 20375260.
Maisano F, Franzen O, Baldus S, et al. Percutaneous mitral valve interventions in the real world. Journal of the American College of Cardiology. 2013;62(12):1052-1061. DOI: 10.1016/j.jacc.2013.02.053. PMID: 23747768.
Dziadzko V, Clavel MA, Dziadzko M, et al. Outcome and undertreatment of multivalvular disease: a population-based analysis. Lancet. 2018;391(10126):1323-1332. DOI: 10.1016/S0140-6736(17)32440-7. PMID: 29397183.
Russo A, Grigioni F, Avierinos JF, et al. Thromboembolic complications after surgical correction of mitral regurgitation: incidence, predictors, and clinical implications. Journal of the American College of Cardiology. 2008;51(12):1203-1211. DOI: 10.1016/j.jacc.2007.11.051. PMID: 18355659.